TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Dec 13, 2022 9:41pm
137 Views
Post# 35169966
RE:RE:RE:Here's the bottom line.
RE:RE:RE:Here's the bottom line."Rathjen and Ladenburg Thalmann may have just killed off both companies."
With 25% of biotech companies trading below cash in recent months these two companies on life support have been given a second chance where many won't be. While there is a ways to go for many to recover and be made whole at least together these companies are viable in a very difficult biotech environment and can push forward. The resulting company still has a tiny market cap in the context of the opportunities with near term catalysts from the clinic to deals. It is diversified as never before. xB3 can now move forward instead of stagnate. Licensing a preclinical asset can also mean giving up 90% or more of the upside for a 5-10% royalty, etc. There's still lots of blue sky and this new company can advance the opportunities internally adding value. Ladenberg is in.